A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

NCT06682572 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Low Grade Serous Ovarian Cancer
Ovarian Cancer

Interventions

DRUG: Avutometinib (VS-6766) + Defactinib (VS-6063)

Sponsor

Verastem, Inc.

Collaborators

[object Object]